학술논문
Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO).
Document Type
Article
Author
Zwimpfer, Tibor A.; Bilir, Esra; Gasimli, Khayal; Cokan, Andrej; Bizzarri, Nicolò; Razumova, Zoia; Kacperczyk-Bartnik, Joanna; Nikolova, Tanja; Pletnev, Andrei; Kahramanoglu, Ilker; Shushkevich, Alexander; Strojna, Aleksandra; Theofanakis, Charalampos; Cicakova, Tereza; Vetter, Marcus; Montavon, Céline; Morgan, Gilberto; Heinzelmann-Schwarz, Viola
Source
Subject
*PLATINUM compounds
*MEDICAL protocols
*CROSS-sectional method
*RESEARCH funding
*HYDROCARBONS
*ALLERGIES
*FEMALE reproductive organ tumors
*SYSTEMATIC reviews
*SURVEYS
*ALLERGY desensitization
*ONCOLOGISTS
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2072-6694
Abstract
Simple Summary: Hypersensitivity reactions (HSRs) to platinum and taxane are common, and desensitization can be used to complete the standard chemotherapy regimen with a good safety profile and high success rate. Our study showed that the use of desensitization for HSRs to taxane and platinum is low in clinical practice. Treatment of HSRs has been shown to be heterogeneous and dependent on the grade of the HSR. Guidelines for the treatment of HSRs to taxane and platinum in gynecologic cancers have been of great interest to clinicians. Our study highlights that the management of platinum and taxane HSRs in gynecological cancers could be standardized and that international guidelines need to be developed. Platinum and taxane chemotherapy is associated with the risk of hypersensitivity reactions (HSRs), which may require switching to less effective treatments. Desensitization to platinum and taxane HSRs can be used to complete chemotherapy according to the standard regimen. Therefore, we aimed to investigate the current management of HSRs to platinum and/or taxane chemotherapy in patients with gynecologic cancers. We conducted an online cross-sectional survey among gynecological and medical oncologists consisting of 33 questions. A total of 144 respondents completed the survey, and 133 respondents were included in the final analysis. Most participants were gynecologic oncologists (43.6%) and medical oncologists (33.8%), and 77.4% (n = 103) were involved in chemotherapy treatment. More than 73% of participants experienced >5 HSRs to platinum and taxane per year. Premedication and a new attempt with platinum or taxane chemotherapy were used in 84.8% and 92.5% of Grade 1–2 HSRs to platinum and taxane, respectively. In contrast, desensitization was used in 49.4% and 41.8% of Grade 3–4 HSRs to platinum and taxane, respectively. Most participants strongly emphasized the need to standardize the management of platinum and taxane HSRs in gynecologic cancer. Our study showed that HSRs in gynecologic cancer are common, but management is variable and the use of desensitization is low. In addition, the need for guidance on the management of platinum- and taxane-induced HSRs in gynecologic cancer was highlighted. [ABSTRACT FROM AUTHOR]